Ignite Creation Date:
2025-12-25 @ 2:10 AM
Ignite Modification Date:
2025-12-31 @ 7:33 PM
Study NCT ID:
NCT01466660
Status:
COMPLETED
Last Update Posted:
2020-04-07
First Post:
2011-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-12-13
Start Date Type:
ACTUAL
Primary Completion Date:
2016-04-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-04-12
Completion Date Type:
ACTUAL
First Submit Date:
2011-11-04
First Submit QC Date:
None
Study First Post Date:
2011-11-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-04-04
Results First Submit QC Date:
None
Results First Post Date:
2017-06-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-26
Last Update Post Date:
2020-04-07
Last Update Post Date Type:
ACTUAL